| clopidogrel / Generic mfg. |
| Not yet recruiting | 4 | 120 | | | Auckland City Hospital., National Heart Foundation (NZ), Greenlane Research and Education Fund | Coronary artery disease | | | | |
ACTRN12613001362785: Do new blood-thinning treatments commenced after cardiac surgery keep By-Pass Grafts open longer ? |
|
|
| Not yet recruiting | 4 | 400 | | | Waikato District Health Board, AstraZenica Limited
Global Commercial Organisation New Zealand | Coronary Artery Graft Patency following Coronary Artery Bypass Graft (CABG) post Acute Coronary Syndrome (ACS) | | | | |
ACTRN12611001132932: Treating Aspirin Resistance with GuidEd Therapy in Diabetes (TARGET-Diabetes) Study |
|
|
| Recruiting | 4 | 400 | | | RMIT University, Diabetes Australia Research Trust | aspirin resistance, type 2 diabetes | | | | |
2004-005174-23: Is smooth muscle mitogenesis down regulated by platelet inactivation with combination antiplatelet therapy after angioplasty for claudication? |
|
|
| Ongoing | 4 | 50 | Europe | Plavix (Clopidogrel), Tablet, Plavix (Clopidogrel) | NHS Grampian | Intermittent claudication = stenosis of superficial femoral artery requiring percutaneous angioplasty | | | | |
ChiCTR-TRC-08000188: Clopidogrel Optimal Loading Dose to Enhance ST-segment resolution in Acute Myocardial Infarction (COLDEST-AMI) |
|
|
| Completed | 4 | 200 | | routine loading dose clopidogreal (300 mg) ;high loading dose clopidogreal (600 mg) | Department Of Cardiology, Shanghai Renji Hospital; Level of the institution：, Science and Technology Commission of Shanghai Municipality | STEMI | | | | |
| Completed | 4 | 252 | | The Patients take Tongxinluo 2.08g together with Aspirin and Clopidogrel before emergency interventional treatment. After surgery, the Patients take 1.04g, t.i.d, Continuing 6 months after acute myocardial infarction. ;The Patients take Tongxinluo 2.08g together with Aspirin and Clopidogrel before emergency interventional treatment. After surgery, the Patients take 1.04g, t.i.d, Continuing 6 months after acute myocardial infarction. | The Fuwai Cardiovascular Disease Hospital of Chinese Medical Sciences Academy; Yiling Pharmaceutical Group of HEBEI, Project funding and matching funds horizontal | Coronary artery disease, acute myocardial infarction | | | | |
2012-000997-53: ANTIPLATELET TREATMENT FOR PREVENTION OF VASCULAR OUTCOMES IN PAD PATIENTS UNDERGOING PERIPHERAL REVASCULARIZATION. TRATTAMENTO ANTIPIASTRINICO NELLA PREVENZIONE DEGLI EVENTI VASCOLARI NEI PAZIENTI AFFETTI DA PAD SOTTOPOSTI A PROCEDURE DI RIVASCOLARIZZAZIONE PERIFERICA. |
|
|
| Ongoing | 4 | 410 | Europe | Gastro-resistant tablet, Film-coated tablet, CARDIOASPIRIN*30CPR GAST 100MG, PLAVIX*28CPR RIV 75MG | AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA, Ministero della Salute - Regione Toscana | Will be enrolled in the study patients suffering from intermittent claudication in whom resulted ineffective both pharmacological and workout therapy- Will be considered eligible patients aged 40-80 inclusive, with an ankle-brachial index (ABI) <0.9 or > 1.3 at basal condition and diametrical arterial stenosis equal or superior to 50% vessel lumen, undergoing peripheral revascularization procedures. Pazienti affetti da claudicatio intermittens nei quali non sono efficaci né il trattamento farmacologico né la terapia basata sull’esercizio fisico. Saranno eleggibili se di età compresa tra i 40 e gli 80 anni, con un indice caviglia-braccio [ankle-brachial index (ABI)] < 0.9 o > 1.3 in condizioni di base e stenosi diametriche delle arterie pari o superiori al 50% del lume vasale, sottoposti a procedure di rivascolarizzazione periferica., Will be enrolled in the study patients reporting a reduced walking autonomy, because an arterial lower extremity circulation impairment. Saranno arruolati nello studio pazienti con ridotta autonomia di marcia a causa di alterazione della circolazione arteriosa degli arti inferiori., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR-TRC-10000776: A Study on the Efficacy and Safety of Telmisartan, Clopidogrelin and Leflunomide in patients with IgA nephropathy |
|
|
| Completed | 4 | 400 | | Telmisartan+ Clopidogrelin placebo + Leflunomide placebo ;Telmisartan + Clopidogrelin+ Leflunomide placebo ;Telmisartan + Clopidogrelin placebo + Leflunomide ;Telmisartan + Clopidogrelin + Leflunomide | Chinese General Hospital of PLA; Beijing Science and Technical Committee, Science and Technology fund of Beijing finance | lgA nephropathy | | | | |
2012-000497-38: VERDI Study (VERifynow in Diabetes non-responsiveness: a study on switching from Clopidogrel to Prasugrel). Estudio VERDI (VERifinow en DIabéticos no respondedores: un estudio sobre el paso de clopidogrel a prasugrel) |
|
|
| Ongoing | 4 | 50 | Europe | Efient, AGRELAN, Tablet, Efient, AGRELAN | Fundación FISEVI, Consejeria de salud | Type 2 diabetic patients revascularized with a stent, who have an acute coronary syndrome without persistent ST segment elevation. Pacientes diabéticos tipo 2 con infarto agudo de miocardio sin elevación de ST sometidos a revascularización con stent., Diabetic patients with myocardial infarction revascularized with a stent. Pacientes diabéticos con infarto de miocardio tratados mediante implante de stent., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2012-003125-24: Evaluation of platelet functional response in patients with acute coronary syndromes without ST-segment elevation (NSTEACS)treated with clopidogrel. Valutazione della risposta funzionale piastrinica in pazienti con sindrome coronaria acuta senza sopraslivellamento del tratto ST (NSTEACS) in trattamento con Clopidogrel. |
|
|
| Ongoing | 4 | 25 | Europe | Film-coated tablet, Tablet | A.O. UNIVERSITARIA INTEGRATA DI VERONA, Regione Veneto | Patients with acute coronary syndromes without ST-segment elevation (NSTEACS). Pazienti con sindrome coronaria acuta senza sopraslivellamento del tratto ST (NSTEACS)., Unstable coronary condition prone to ischaemic recurrences and other complications that may lead to death or myocardial infarction in the short and long term. Condizione coronarica instabile con episodi ischemici e altre complicazioni che possono portare a infarto nel breve e lungo termine, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Completed | 4 | 100 | | Clopidogrel Hydrogensulfate Tablets ;none | Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine; Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, scientic fund of department | coronary atherosclerotic heart disease | | | | |
ChiCTR-TRC-11001249: Comparision of different dose of clopedogrel plus aspirin and aspirin alone for patients with drug-eluting stent implanting one year later: a prospective,randomized, multicenter, observation study |
|
|
| Completed | 4 | 800 | | aspirin 100mg per day plus clopidogrel 25mg per day ;aspirin 100mg per day plus clopidogrel 50mg per day ;aspirin 100mg per day plus clopidogrel 275mg per day ;aspirin 100mg per day plus clopidogrel 275mg per day | Guangdong General Hospital; Science and technology plan program of Guangdong Province, Science and technology plan program of Guangdong Province, China | Coronary heart disease | | | | |
ChiCTR-TRC-11001807: Individual applications of clopidogrel after Percutaneous coronary intervention |
|
|
| Completed | 4 | 600 | | According CYP2c19 genotype of antiplatelet therapy ;Clopidogrel 75mg / d | 1st Affiliated Hospital of Xinjiang Medical University; 1st Affiliated Hospital of Xinjiang Medical University, Science and technology projects in Urumqi | coronary artery disease | | | | |
ChiCTR-TRC-11001770: A randomized, parallel-group, single-center clinical study to examine the safety and effectiveness between argatroban and unfractionated heparin as anticoagulation in combination with clopidogrel and aspirin in coronary heart disease patients with moderate to high bleeding risk undergoing elective p |
|
|
| Completed | 4 | 200 | | Heparin ;argatroban | The Cardiovascular department, the General Hospital of PLA, No.28 Fuxing Road, Beijing, China; The Cardiovascular department, the General Hospital of PLA, No.28 Fuxing Road, Beijing, China, TIPR pharmaceutical Responible Co.,Ltd | Coronary Artery Disease; Angina Unstable | | | | |
ChiCTR-TRC-10001056: Effect of different anti-platelet strategies on the long-term outcome after sirolimus drug-eluting stent implantation(EASTS study) |
|
|
| Completed | 4 | 3792 | | placebo 75mg qd 12 months ;clopidogrel 75mg qd 12 months ;clopidogrel 50mg 1 month, then 25mg 1 month, placebo 75mg qd 10 months | Zhejiang University; Level of the institution：, Self-financing | coronary artery disease | | | | |
ChiCTR-TRC-14004226: Effect of tirofiban on coronary microcirculation of PCI operation and research on the mechanism |
|
|
| Completed | 4 | 119 | | Oral aspirin 300mg and clopidogrel + tirofiban + directly perform PCI inter-coronary artery ;Oral aspirin 300mg and clopidogrel + directly perform PCI inter-coronary artery | Tianjin Tifth Central Hospital; Tianjin Tifth Central Hospital, Health bureau of Tianjin City | Acute myocardial infarction | | | | |
ChiCTR-OCH-11001198: DNA pooling-based genome-wide screen for genetic determinants of response to antiplatelet therapy after PCI and validation |
|
|
| Completed | 4 | 3500 | | Clopidogrel, interacting drugs, genetic variation, plasma biomarker | Guangdong General Hospital, Guangdong Academy of Medical Sciences; National Natural Science Foundation of China, National Natural Science Foundation of China | Coronary artery disease | | | | |
ChiCTR-OCS-12001901: The relationship between the genetic polymorphism of CYP2C19*2, *3 and the clinical efficacy of clopidogrel: a systematic review |
|
|
| Completed | 4 | 150 | | Nil | Department of Education and Science Technology, Ministry of Health; Xuan Wu Hospital, Capital Medical University, Ministry of Health | Coronary heart disease | | | | |
ChiCTR-TRC-12002607: The effect of different proto pump inhibitor in dual anti - platelet therapy with aspirin and clopidogrel in patients with acute coronary syndrome |
|
|
| Completed | 4 | 400 | | omeprazole ;lansoprazole ;Rabeprazole ;Rabeprazole | Affiliated Jiangyin Hospital, College of Medicine, Southeast University; Affiliated Jiangyin Hospital, College of Medicine, Southeast University, Supported by the Research Project and investigator | coronary heart disease | | | | |
ChiCTR-TRC-13003923: The research of the ticagrelor and the clopidogrel in improving the slow flow / no- reflow in the interventional surgery of acute coronary syndrome (ACS) patients and the impact of cardiovascular and cerebrovascular events in post-operative |
|
|
| Completed | 4 | 100 | | Ticagrelor ;clopidogrel | Cardiology of Zhujiang hospital; Level of the institution：, China cardiovascular physician research fund | Acute coronary syndrome | | | | |
ChiCTR-TRC-12002673: Impact of obstructive sleep apnea syndrom on clinical outcome in patients treated with drug-eluting stent for coronary artery disease |
|
|
| Completed | 4 | 2000 | | Loading dose of clopidogrel ;Loading dose of clopidogrel | Nanjing First Hospital, Nanjing Medical Hospital; Level of the institution：, Selffinance | Coronary artery disease | | | | |
ChiCTR-TRC-14004377: The short-term clinical investigation of ticagrelor in reducing cardiovascular MACEs for elective PCI patients with stable coronary heart disease. |
|
|
| Completed | 4 | 100 | | Taking loading dose(180mg) Ticagrelor before PCI and maintenance dose 90mg Bid ;Taking maintenance dose (90mg Bid) Ticagrelor after PCI ;Clopidogrel 75mg Qd | Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Level of the institution：, Self-raised fund | coronary heart disease | | | | |
2015-004144-20: Safety profile evaluation of TICagrelor Alone compared to a combination of lysine acetylsalicylate - Clopidogrel in the context of Transcatheter Aortic Valve Implantation (TAVI) Evaluation du profil de sécurité du TICagrelor utilisé seul en comparaison avec une association acétylsalicylate de lysine-clopidogrel dans le contexte de l’implantation de valve aortique percutanée (TAVI) |
|
|
| Ongoing | 4 | 308 | Europe | Coated tablet, Powder and solvent for oral solution, Brilique 90mg, Plavix 300 mg, Plavix 75mg, Kardegic 75mg | CHU de Bordeaux, CHU de Bordeaux | Aortic valve stenosis Sténose de la valve aortique, Aortic valve stenosis Sténose de la valve aortique, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2006-006971-19: Effect of Aggrenox® / Asasantin® Retard compared with Clopidogrel on Endothelial function as measured by Microalbuminuria, Inflammatory markers CRP, MCP-1, and MMP-9 in Patients with Type 2 Diabetes Mellitus and a history of TIA or stroke. |
|
|
| Ongoing | 4 | 60 | Europe | Asasantin Retard, Plavix, Asasantin Retard, Plavix | Aker universitetssykehus | Patients with Type 2 Diabetes Mellitus and a history of TIA or stroke. | | | | |
2005-000960-25: Role of Inflammation and Platelet Activation in the adverse Cardiovascular Outcomes of Patients with Critical Limb Ischaemia - a double-blind randomised trial of Clopidogrel. |
|
|
| Ongoing | 4 | 200 | Europe | Plavix, Plavix, Plavix | Lothian NHS trust | Peripheral Vascular Disease (Critical Limb Ischaemia) | | | | |
2004-000517-19: PRETREATMENT WITH HIGH DOSE CLOPIDOGREL FOR REDUCTION OF THROMBOTIC EVENTS AFTER ELECTIVE CORONARY TERRITORY STENTING WITH DRUG ELUTING STENTS: ThePROTECTED Study |
|
|
| Ongoing | 4 | 100 | Europe | PLAVIX 75mg or Clopidogrel 75mg | Blackpool Fylde & Wyre Healthcare NHS Trust | PERCUTANEOUS CORONARY INTERVENTION( USING DRUG ELUTING STENTS) | | | | |
2005-003927-38: Platelet adhesion assay for evaluation of anti-platelet treatment in coronary heart disease |
|
|
| Ongoing | 4 | 30 | Europe | Trombyl, Plavix, | Per Whiss, Faculty of Health Sciences | Coronary heart disease, angina pectoris | | | | |
2005-004283-23: An evaluation of potential therapies to inhibit cerebral emboli in dementia |
|
|
| Ongoing | 4 | 220 | Europe | Clopidogrel, Atorvastatin, | South Manchester University Hospital | Alzheimer\'s Disease and Vascular Dementia | | | | |
2006-006695-38: Evaluation pharmacologique des antagonistes du récepteur P2Y12 à l\'ADP chez le volontaire sain |
|
|
| Ongoing | 4 | 6 | Europe | PLAVIX (Clopidogrel), KARDEGIC (acétylsalicylate de lysine), PLAVIX (Clopidogrel), KARDEGIC (acétylsalicylate de lysine) | CHU Toulouse | Volontaires sains | | | | |
2007-002652-42: The use of clopidogrel and aprotonin in off pump coronary artery bypass grafting |
|
|
| Ongoing | 4 | 270 | Europe | clopidogrel, aprotinin, Plavix, Trasylol, Plavix, Trasylol | Royal Brompton and Harefield NHS Trsut | Bleeding after coronary artery bypass grafting | | | | |
2007-003907-11: Estudio aleatorizado, unicéntrico, que compara un régimen de dosis elevada de clopidogrel frente a la dosis estándar en pacientes diabéticos tipo 2 revascularizados mediante una estrategia invasiva percutanea con stent farmacoactivo.\" Estudio CANDY (Clopidogrel and Aspirin No responsiveness in Diabetes tYpe 2 study). |
|
|
| Ongoing | 4 | 40 | Europe | Clopidogrel, Clopidogrel, | Grupo de Investigación ICP | Síndrome coronario agudo (angina inestable / infarto agudo de miocardio sin elevación de ST) en combinación con Ácido Acetilsalicílico | | | | |
2007-007638-21: Is cessation of clopidogrel therapy associated with rebound of platelet activity in stable vascular disease patients? |
|
|
| Ongoing | 4 | 172 | Europe | Plavix, Plavix, Plavix, Plavix | University of Aberdeen, NHS Grampian Health Board | Cardiovascular disease | | | | |
2008-001604-23: A double blind placebo controlled trial investigating the efficacy of Clopidogrel as prophylactic treatment for migrane. |
|
|
| Ongoing | 4 | 286 | Europe | PLAVIX, PLAVIX | Guy\'s & St Thomas\' NHS Foundation Trust | Migraine | | | | |
2009-011543-40: Assessment of platelet inhibitory response to clopidogrel when coadministered with a proton pump inhibitor |
|
|
| Ongoing | 4 | 72 | Europe | Omeprazole, Pariet (Rabeprazole), Zantac, Omeprazole (Losec), Pariet, Zantac (Ranitidine), Omeprazole (Losec), Pariet, Zantac (Ranitidine) | Papworth Hospital | To investigate in patients undergoing elective coronary stenting, the interaction between omeprazole, rabeprazole and ranitidine on clopodogrel inhibition of platelet activity in wild type (wt/wt) CYP2C19 “extensive metabolisers”, using VerifyNow-P2Y12 assay clopidogrel assay. We will also indirectly assess the effect of clopidogrel on acid suppression by measuring gastrin hormone levels that are directly related to stomach pH. | | | | |
2009-014343-36: RANDOMIZED TRIAL OF PRASUGREL PLUS BIVALIRUDIN VERSUS CLOPIDOGREL PLUS HEPARIN IN PATIENTS WITH ACUTE STEMI BAVARIAN REPERFUSION ALTERNATIVES EVALUATION [BRAVE-4] TRIAL |
|
|
| Ongoing | 4 | 1240 | Europe | Prasugrel, Bivalirudin, Heparin, Plavix, B01AC22, Efient, Angiox, Heparin-Natrium, Plavix, Efient, Angiox, Heparin-Natrium, Plavix | Deutsches Herzzentrum | Acute myocardial infarction | | | | |
2008-006371-67: EFFECT OF THIENOPYRIDINE DERIVATIVE (CLOPIDOGREL) ON THE DISPOSITION OF EFAVIRENZ AND NEVIRAPINE IN HIV POSITIVE PATIENTS |
|
|
| Ongoing | 4 | 37 | Europe | plavix, Nevirapine, Efavirenz, B01AC04, J05AG03, Plavix (Sanofi Synthelabo, Guildford, United Kingdom), viramune, sustiva;stocrin, Plavix (Sanofi Synthelabo, Guildford, United Kingdom), viramune, sustiva;stocrin | Royal Liverpool and Broadgreen University Hospital, University of Liverpool | To determine whether anti-platelet agent clopidigrel influences the disposition of NNRTIs (efavirenz and nevirapine) | | | | |
2011-001686-40: Ticagrelor vs. Prasugrel in patients with Clopidogrel low response - ISAR ADAPT-PF Ticagrelor vs. Prasugrel bei Patienten mit unzureichendem Ansprechen auf Clopidogrel - ISAR ADAPT-PF |
|
|
| Ongoing | 4 | 60 | Europe | Efient, Brilique, Efient, Brilique, Efient, Brilique | German Heart Centre Munich, Department of Cardiovascular Diseases, German Heart Centre Munich, Department of Cardiovascular Diseases | Effect of Ticagrelor and Prasugrel in patients with insufficient responding to Clopidogrel after coronary intervention (non-inferiority of Ticagrelor vs. Prasugrel) Wirkung von Ticagrelor und Prasugrel bei Patienten mit insuffizientem Ansprechen auf Clopidogrel nach Koronarintervention (Nicht-Unterlegenheit von Ticagrelor gegenüber Prasugrel) | | | | |
2013-000472-16: COMPARISON OF SWITCHING PRASUGREL OR TICAGRELOR IN ELDERLY PATIENTS WITH CORONARY ARTERY DISEASE EFECTOS DEL CAMBIO A PRASUGREL O TICAGRELOR EN PACIENTES ANCIANOS CON ENFERMEDAD CORONARIA |
|
|
| Ongoing | 4 | 60 | Europe | efient 5 mg, BRILIQUE 90 mg, efient 5 mg, BRILIQUE 90 mg | Fundación Interhospitalaria para la Investigación Cardiovascular, Fundación Interhospitalaria para la Investigación Cardiovascular | CORONARY ARTERY DISEASE ENFERMEDAD CORONARIA | | | | |
| Recruiting | 4 | 296 | | Clopidogrel + Aspirin + Warfarin ;Ticagrelor + Warfarin | ZhongDa Hospital affiliated to Southeast University China; ZhongDa Hospital, AstraZeneca Pharmaceutical Co., Ltd. | Persistent or Permanent Atrial Fibrillation and Coronary artery disease | | | | |
2012-003897-21: Effects of TIcaGREloR on Circulating Microparticles and Micro-RNAs in patients with Non ST Elevation Acute Coronary Syndromes Effetto del TIcaGREloR sulle Microparticelle Circolanti e sui Micro-RNAs nei pazienti con Sindrome Coronarica Acuta senza Sopraslivellamento del Tratto ST |
|
|
| Ongoing | 4 | 64 | Europe | BRILIQUE*60CPR RIV 90MG, PLAVIX*28CPR RIV 75MG, BRILIQUE*60CPR RIV 90MG, PLAVIX*28CPR RIV 75MG | POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI, Astrazeneca | Non ST Elevation Acute Coronary Syndromes SINDROME CORONARICA ACUTA SENZA SOPRASLIVELLAMENTO DEL TRATTO ST | | | | |
2015-005566-33: APixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF) Apixaban versus Phenprocoumon: Orale Antikoagulation plus Plättchenaggregationshemmung bei Patienten mit akutem Koronarsyndrom und Vorhofflimmern |
|
|
| Not yet recruiting | 4 | 400 | Europe | Eliquis, Marcumar, ASS, Plavix, Film-coated tablet, , Tablet, Eliquis | Klinikum der Universitaet Muenchen AoeR, Deutsches Zentrum für Herz-Kreislauf-Forschung, Bristol-Myers Squibb | Patients with acute coronary syndrome and atrial fibrillation Patienten mit akutem Koronarsyndrom und Vorhofflimmern, Patients with acute coronary syndrome and atrial fibrillation Patienten mit akutem Koronarsyndrom und Vorhofflimmern, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Recruiting | 4 | 160 | | NA | Nanjing First Hospital; Nanjing First Hospital, Natural Science Foundation of Jiangsu | coronary artery disease | | | | |
ChiCTR-IPR-14005454: Prehospital Clopidogrel versus Ticagrelor in Patients going Primary Percutaneous Coronary Intervention with Large Anterior Myocardial Infarction on platelet aggregation and myocardial perfusion |
|
|
| Recruiting | 4 | 108 | | Clopidogrel 600mg ;Ticagrelor 180mg ;Ticagrelor 180mg | Guangzhou military hospital; None, Project funding | Acute ST-Segment elevation myocardial infarction | | | | |
ChiCTR-IPR-15006826: Dual Antiplatelet versus Defibrinogenation Therapy in Acute Ischemic Stroke: a Parallel Randomized, Open-label, Multicenter, Prospective study |
|
|
| Recruiting | 4 | 400 | | Clopidogrel and aspirin ;Batroxobin | The General Hospital of Shenyang Military; The General Hospital of Shenyang Military, fund | Acute Ischemic Stroke | | | | |
NCT02629367: Influence of Vorapaxar on Thrombin Generation and Coagulability |
|
|
| Not yet recruiting | 4 | 100 | US | Vorapaxar, Asprin, Clopidogrel | Inova Health Care Services | Coronary Artery Disease | 01/17 | 03/17 | | |
ChiCTR-IPR-14005315: The effect of thrombosis aspiration combined ticagrelor on myocardial perfusion and prognosis of primary PCI for STEMI |
|
|
| Recruiting | 4 | 300 | | asprin+ticagrelor+heparin ;asprin+ticagrelor+bivalirudin ;asprin+clopidogrel+heparin | Kanghua Hospital; Kanghua Hospital, Dongguan Kanghua Hospital Heart Center Sunshine Fund | ST segment elevation myocardial infarction | | | | |
| Recruiting | 4 | 600 | | Aspirin and clopidogrel and heparin ;Aspirin and ticagrelor and bivalirudin | The Second Hospital, Hebei Medical University; The Second Hospital, Hebei Medical University, government fund | coronary heart disease | | | | |
2016-003325-41: PREemptive Pharmacogenomic testing for Preventing Adverse drug REactions (PREPARE) |
|
|
| Ongoing | 4 | 450 | Europe | Syrup, Tablet, Capsule, hard, Powder for injection, Capsule, Solution for injection, Concentrate for solution for infusion, Powder for solution for infusion, Codeine, Acenocoumarol, Amitriptyline, Aripiprazole, Atomoxetine, Atorvastatine, Azathioprine, Capecitabine, Carbamazepine, Citalopram, Clomipramine, Clopidogrel, Clozapine, Efavirenz, Escitalopram, Flecainide, Flucloxacillin, Fluorouracil, Haloperidol, Irinotecan, Mercaptopurine, Metoprolol, Oxycodone, Paroxetine, Phenprocoumon, Phenytoin, ORAP 1 mg Tabletten, Propafenone, Sertraline, Simvastatin, Tacrolimus, Tamoxifen, Tegafur, Tioguanine, Tramadol, Venlafaxine, Voriconazole, Zuclopenthixol, Ethinylestradiol, ORAP 4 mg Tabletten | Leiden University Medical Center, Leiden University Medical Center | Adverse drug reactions, Side-effects, Not possible to specify | | | | |
| Recruiting | 4 | 400 | | PCI for stenting 300 mg loading doses of clopidogrel and aspirin | Nanjing First Hospital; Nanjing First Hospital, Science and Technology Department of Jiangsu Province | coronary artery disease | | | | |
| Ongoing | 4 | 100 | Europe | BRILIQUE, PLAVIX, ND, Film-coated tablet, BRILIQUE - 90 MG - COMPRESSE RIVESTITE CON FILM - USO ORALE - BLISTER(PVC/PVDC/ALU) 60 COMPRESSE, PLAVIX - 75 28 COMPRESSE FILMRIVESTITE 75 MG IN BLISTER | UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI, AstraZeneca | Patients with multivessel coronary artery disease requiring staged, ischemia-guided PCI Pazienti con malattia coronarica multivasale che richiedono PCI guidata, ND ND, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2017-003411-19: Compatibility of clopidogrel prepared for administration through nasogastric tube with enteral nutrition (CPU-003) Kompatibilita klopidogrelu připraveného pro podání do nasogastrické sondy s enterální výživou (CPU-003) |
|
|
| Ongoing | 4 | 10 | Europe | Film-coated tablet, Trombex | Fakultní nemocnice u sv. Anny v Brně, Fakultní nemocnice u sv. Anny v Brně | healthy volunteers zdraví dobrovolníci, healthy volunteers zdraví dobrovolníci, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
| Not yet recruiting | 4 | 200 | | oral administration of clopidogrel according to CYP2C19 genotype ;oral administration of clopidogrel 75mg/d | Tongji Hospital affiliated to Tongji University; None, Science and Technology Commission of Shanghai Municipality | coronary artery disease | | | | |
2017-001834-25: To compare two medication therapies to prevent thrombus (blood cloth) formation following the successful treatment of a coronary heart disease with expansion of coronary stent (metallic tube) covered with medication (Drug Eluting Stent-DES): a shortened versus a prolonged dual antiplatelet therapy (DAPT, drugs that inhibit bloodplatelets, blood cells involved in the thrombus formation process). Das Ziel dieser Studie ist, zwei medikamentöse Therapien zur Prävention von Thrombenbildung (Blutgerinnsel) miteinander zu vergleichen, nach erfolgreicher Behandlung einer koronaren Herzkrankheit mittels eines Medikament-freisetzenden Stents (Drug Eluting Stent, DES). Verglichen wird dabei eine zeitlich verkürzte mit einer zeitlich verlängerten dualen Antiplättchentherapie (DAPT, medikamentöse die Bluttplättchen hemmen, d.h Blutzellen die an der Bildung von Thrombosen beteiligt sind) |
|
|
| Ongoing | 4 | 4300 | Europe | ADIRO, Brilique, Plavix, NA, Tablet, ADIRO 100 mg comprimidos gastrorresistentes EFG Ácido acetilsalicílico, Brilique 60 mg comprimidos recubiertos con película, Plavix 75 mg comprimidos recubiertos con película | ECRI-9, Terumo Europe NV, TERUMO EUROPE NV | High bleeding risk population represents a significant proportion of coronary artery disease (CAD) patients undergoing coronary stent implantation. Decisions regarding the duration of dual antiplatelet therapy (DAPT) after stent implantation are difficult, especially after implantation of newer generation drug eluting stents (DES) due to conflicting results from recent trials. High bleeding risk patients either male or female eligible for percutaneous coronary intervention will be included. Bei Patienten mit koronarer Krankheit stellt die Gruppe derjenigen mit einem hohen Blutungsrisiko einen Anteil der koronaren Stentimplantationen dar. Aufgrund widersprüchlicher Ergebnisse aus jüngsten Studien ist die Entscheidung bezüglich der Dauer der DAPT im Anschluss an eine Stentimplantation, vor allem nach Implantation von Medikamente-freisetzenden Stents der neueren Generation, schwierig. Patienten mit einem hohen Blutungsrisiko, die ein PCI haben können, werden in die Studie berechtigt, Patients with different levels of chest pain, due to poor blood flow to the heart, and an increased risk for bleeding. A stent is placed to reopen the artery followed by treatment with medicines. Patienten mit verschiedenen Schmerzen, wegen des schlechten Blutflusses zum Herzen und ein erhöhtes Blutungsrisiko. Ein Stent wird implantiert um ein verengtes bzw. blockiertes Gefäß wieder zu öffnen, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR-OPC-17011769: The Study of Individualized Administration of Clopidogrel under the Guidance of Gene Polymorphism and Platelet Activity Detection |
|
|
| Recruiting | 4 | 280 | | Nil | Medical Ethics Committee of Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital; Medical Ethics Committee of Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Sichuan provincial health and family planning commission | coronary heart disease | | | | |
2018-000608-40: Aspirin versus Aspirin plus Clopidogrel in Patients Undergoing Transcatheter Aortic ValveReplacement: a Randomized Multicenter Study Confronto Randomizzato tra Acido Acetil Salicilico versus Acido Acetil Salicilico più Clopidogrel dopo Impianto di Protesi Valvolare Aortica Trans-Catetere (studio No-DAPT-TAVI) |
|
|
| Ongoing | 4 | 762 | Europe | clopidogrel, clopidogrel, Powder for oral solution, Film-coated tablet, CARDIRENE - 75 MG POLVERE PER SOLUZIONE ORALE 30 BUSTINE, CLOPIDOGREL DOC GENERICI - 75 MG COMPRESSE RIVESTITE CON FILM 30 COMPRESSE IN BLISTER PVC/PE/PVDC/AL | AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI, RF-2016 (Ministero della Salute) | valvular aortic stenosis submitted to TAVI stenosi valvolare aortica sottoposti ad una TAVI, valvular aortic stenosis submitted to TAVI stenosi valvolare aortica sottoposti ad una TAVI, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2014-002171-29: Peri-interventional intensified versus moderate platelet inhibition in patients with coronary artery disease without myocardial infarction |
|
|
| Ongoing | 4 | 2240 | Europe | Film-coated tablet, Efient, Plavix | Hospital of the University of Munich, Grosshadern, Hospital University of Munich, Grosshadern | Biomarker-negative patients with an indication for percutaneous coronary intervention, Patient with chest pain without laboratory and electrocardiographic signs of acute heart attack who need a treatment of coronary blockages, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Ongoing | 4 | 1806 | Europe | Capsule, Tablet, , Brilique, Aspirin, Clopidogrel | University Medical Center Utrecht, Antonius fund, Stichting Lijf en Leven, Dutch endovascular alliance, UMCU Vascular surgery fund | It is known that the atherothrombotic cardiovascular adverse event rate in patients with peripheral artery disease (PAD) is high. Also patency rates after (endo)vascular interventions in PAD patients are lower than in other arterial segments. In PAD patients the main focus in studies is on the technical aspects and success, while less attention has been paid to antiplatelet management, despite its significant effect on morbidity and mortality risk. perifeer vaatlijden, Peripheral arterial disease typically strikes arteries of the legs. Arteriosclerosis narrows arteries thereby decreasing the amount of blood and oxygen flowing to the tissues., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR-ONRC-13003436: A Multi-center Clinical Study: Chinese Patent Foramen Ovale and Paradoxical Embolism |
|
|
| Recruiting | 4 | 200 | | use domestic made or imported occluder; oral clopidogrel 50-75mg/daily for one month; aspirin enteric-coated tablets 3mg/kg/d for 6 months; after 6 moths the doctor makes decision whether contineu to use anti-platelet therapy or not ;Aspirin or warfarin or aspirin+ warfarin | The First Hospital Affiliated to Xi'an Jiaotong University; The First Hospital Affiliated to Xi'an Jiaotong University, NA | Ischemic stroke | | | | |
ChiCTR2000030143: Study for the antithrombotic therapy of rivaroxaban and clopidogrel after PCI in Chinese patients with acute coronary syndrome complicated with atrial fibrillation |
|
|
| Completed | 4 | 100 | | Rivaroxaban (15mg 1/ d) + clopidogrel (75mg 1/ d) | The second hospital of hebei medical university; the Second Hospital of Hebei Medical University, None | coronary heart disease | | | | |
2018-000532-94: Optimal duration of dual anti-platelet therapy in patients undergoing endovascular revascularization of the superficial femoral artery. Durata ottimale della doppia terapia antiaggregante in pazienti sottoposti a rivascolarizzazione endovascolare dell’arteria femorale superficiale. |
|
|
| Ongoing | 4 | 78 | Europe | Acido acetilsalicilico, Clopidogrel, [Acido acetilsalicilico], [Clopidogrel], Gastro-resistant tablet, Film-coated tablet, ACIDO ACETILSALICILICO MYLAN - 100 MG COMPRESSE GASTRORESISTENTI 20 COMPRESSE IN BLISTER AL/AL, PLAVIX - 75 28 COMPRESSE FILMRIVESTITE 75 MG IN BLISTER | FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO, UNIVERSITA' DEGLI STUDI DI PAVIA | Patients with diagnosis of lower limbs PAOD, ranging from stage 2 to 5 according to Rutherford classification and lesions of the SFA treated by endovascular revascularization PAZIENTI AFFETTI DA ARTERIOPATIA OBLITERANTE CRONICA PERIFIERICA (AOCP) STADIO 2-5 SECONDO RUTHERFORD SOTTOPOSTI A RIVASCOLARIZZAZIONE ENDOVASCOLARE DELL'ARTERIA FEMORALE SUPERFICIALE, PATIENTS WITH LOWER LIMBS ISCHEMIA TREATED BY ENDOVASCULAR REVASCULARIZATION ISCHEMIA DEGLI ARTI INFERIORI TRATTATI CON PROCEDURA ENDOVASCOLARE A LIVELLO DELLA FEMORALE SUPERFICIALE, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2018-003299-11: Can additional treatment with a third blood thinning medication reduce the risk of further clots in heart arteries, in patients with a recent heart attack who are already taking two blood thinning medications. |
|
|
| Not yet recruiting | 4 | 150 | Europe | Rivaroxaban, Clopidogrel, Ticagrelor, Tablet, Film-coated tablet, Rivaroxaban, Clopidogrel, Ticagrelor | East and North Hertfordshire NHS Trust, Bayer PLC | Acute Coronary Syndrome, Heart attack, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR-OPN-15006260: Investigation on the effects of genetic polymorphisms and epigenetic modifications in gene encoding P2Y12 receptor signaling molecule on antiplatelet activity and clinical efficacy of clopidogrel |
|
|
| Recruiting | 4 | 1000 | | Patients were administered 300mg loading dose of clopidogrel before PCI and received a 75-mg/d maintenance dosage of clopidogrel and 100 mg/d of aspirin for a year. | Institute of Clinical Pharmacology, Central South University; Institute of Clinical Pharmacology, Central South University, Chinese National Science Foundation (81422052) and Special topic of the major subject of national science and technology (2013ZX09509107) | acute coronary syndromes | | | | |
ChiCTR-IPR-16009179: The influence of the prognosis of increasing the antiplatelet therapy of the patient of ACS before PCI |
|
|
| Recruiting | 4 | 280 | | Bivalirudin + ticagrelor + aspirin ;Ticagrelor + aspirin + heparin ;Aspirin + clopidogrel + aspirin ;Heparin + clopidogrel + aspirin | The second hospital of Hebei Medical University; The second hospital of Hebei Medical University, self-raised | Coronary Heart Disease | | | | |
ChiCTR1800015104: Study on individualized antithrombotic therapy for high-risk groups-A feasibility study on the clinical prognosis of patients with coronary heart disease and diabetes mellitus |
|
|
| Recruiting | 4 | 300 | | Aspirin + clopidogrel ;aspirin + tiglielot | Department of Cardiology;The Second Affiliated Hospital of Army Medical University; Xinqiao Hospital, National key research and development plan | Coronary atherosclerotic heart disease | | | | |
2010-024667-40: Doelmatigheid van een op het CYP2C19 genotype gebaseerde plaatjesremmende farmacotherapie bij patienten met een myocardinfarct die worden gedotterd. |
|
|
| Not yet recruiting | 4 | 2700 | Europe | Tablet, Plavix, Efient, clopidogrel, Brilique | St. Antonius Hospital, St. Antonius Hospital, ZonMw | ST-segment myocardial infarction (STEMI) followed by immediate percutaneous coronary intervention with stent implantation, myocardial infarction, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR1800015065: Indobufen in diabetic nephrotic syndrome in patients with deep venous thrombosis prevention and treatment of clinical research |
|
|
| Recruiting | 4 | 176 | | Indobufen tablets ;Clopidogrel | China-Japan Friendship Hospital Clinical Research Ethics Committee; China-Japan Friendship Hospital Clinical Research Ethics Committee, None | Diabetic nephropathy syndrome | | | | |
ChiCTR1800019333: Effects of different antiplatelet drugs on adenosine concentration in healthy crowd |
|
|
| Recruiting | 4 | 16 | | oarl ticagrelor ;clopidogrel | Shanghai Changhai Hospital; Shanghai Changhai Hospital, Self-raised Funds | Coronary heart disease | | | | |
ChiCTR1900024834: Effect of low-dose versus standard-dose Ticagrelor platelet inhibition in medically managed Chinese patients with ACS: an investigator-initialized, prospective, single-center, open-label, parallel-group randomized controlled trial |
|
|
| Recruiting | 4 | 300 | | Aspirin, 75-150mmg, Q.D. ;Aspirin, 75-150mmg, Q.D., combined with Ticagrelor, 60mg, B.I.D. ;Aspirin, 75-150mmg, Q.D., combined with Clopidogrel, 50-75mg, Q.D. | Fuwai Central China Cardiovascular Hospital; Fuwai Central China Cardiovascular Hospital, FuWaiHuaZhong Cardiovascular hospital | acqute coronary syndrome | | | | |
ChiCTR-IIR-17013505: A randomized controlled trial of ind0bufen versus asPirin aftercoronary drug-eluting stentimplantaTION: The OPTION trial |
|
|
| Recruiting | 4 | 4460 | | Indobufen: 100mg/bid +Clopidogrel: 75mg/qd ;Aspirin: 75mg/qd+Clopidogrel: 75mg/qd | Zhongshan Hospital affiliated to Fudan University; Zhongshan Hospital affiliated to Fudan University, None | Coronary atherosclerotic heart disease | | | | |
ChiCTR1800015314: The efficacy of Clopidogrel on patients of different CYP2C19 genotypes under the guidance of thromboelastogram |
|
|
| Recruiting | 4 | 100 | | antiplatelet agent ;antiplatelet agent | Department of Neurology, Zhujiang Hospital of Southern Medical University; Zhujiang Hospital, Self-financing | Ischemic cerebrovascular diseases | | | | |
ChiCTR1800017008: Effect of trimetazidine on autonomic nervous function in patients undergoing percutaneous coronary intervention |
|
|
| Not yet recruiting | 4 | 400 | | Routine protocol + Trimetazidine ;Routine protocol, include Low-molecular heparin, aspirin, clopidogrel, statin, ACEI or ARB, purge - receptor blockers and nitrates, depends on status of the disease | the Second Hosptial of Hebei Medical University; the Second Hosptial of Hebei Medical University, Self - financing | Coronary Heart Disease | | | | |
| Completed | 4 | 6 | US | Clopidogrel, Plavix, Aspirin | University of Maryland, Baltimore | Heart Diseases, Coronary Disease, Coronary Artery Disease, Cardiovascular Diseases, Myocardial Ischemia, Artery Occlusion, Aspirin Sensitivity, Clopidogrel, Poor Metabolism of, Platelet Dysfunction, Platelet Thrombus | 01/20 | 01/20 | | |
ChiCTR1800014852: Dual antiplatelet therapy contains rivaroxaban in advanced age patients with Atrial Fibrillation and Acute Coronary Syndromes without revascularization |
|
|
| Recruiting | 4 | 300 | | aspine plus clopidogrel ;aspine plus rivaroxaban ;clopidogrel plus rivaroxaban | Tianjin Union Medical Center; Tianjin Union Medical Center, self-raised | Acute coronary syndrome | | | | |
ChiCTR1900026002: Clinical efficacy of Xuefu Zhuyu Capsule combined with clopidogrel in the treatment of coronary heart disease after PCI for one year |
|
|
| Recruiting | 4 | 144 | | Xuefu Zhuyu Capsule + Clopidogrel Bisulfate Tablets ;Clopidogrel Bisulfate Tablets | The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine; The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin Hongrentang Pharmaceutical Co., Ltd. | coronary heart disease | | | | |
ChiCTR-OPN-16007931: The clinical efficacy research for the treatment among intravenous unfractionated heparin, two antiplatelet agents (clopidogrel and aspirin)and single antiplatelet agent (aspirin) to acute cerebral infarction and transient ischemic attack(TIA). |
|
|
| Recruiting | 4 | 588 | | Daily given unfractionated 100mg by intravenous, continuous 5-7 days.Then the operator give patients with aspirin 200mg/day for 7 days. 15-90 days give aspirin 100mg/day. ;The operator give patient with clopidogrel 300 mg +aspirin 100mg on the first day;2-14 days give Dual Antiplatelet Therapy: clopidogrel 75 mg/d +aspirin 100 mg/d .15-90 days give aspirin 100mg/day. ;The operator give patient with aspirin 300mg on the first day; 2-14 days give aspirin 200 mg/d .15-90 days give aspirin 100mg/day. | The Department of Neurology, The Second Affiliated Clinical Hospital Of Harbin Medical University; The Second Affiliated Clinical Hospital Of Harbin Medical University, No | Acute cerebral infarction, transient ischemic attack | | | | |
NCT03008083: Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation |
|
|
| Recruiting | 4 | 2446 | RoW | 3 months DAPT, Ticagrelor (180 mg/day) or Clopidogrel (75 mg/day), 12 months DAPT | Shanghai MicroPort Medical (Group) Co., Ltd. | Drug-Eluting Stents, Percutaneous Coronary Intervention | 12/20 | 10/22 | | |
2020-004913-11: Prescribing antithrombotic therapy in peripheral arterial disease, based on a DNA test. Beter voorschrijven van bloedverdunners bij perifeer arterieel vaatlijden op basis van DNA onderzoek. |
|
|
| Ongoing | 4 | 2244 | Europe | Clopidogrel, Rivaroxaban, Aspirin, Coated tablet, Clopidogrel, Rivaroxaban, Aspirin | Radboudumc, ZE&GG ZonMw | Symptomatic or stable pheripheral artery disease Lower extremity arterial disease., Lower extremity arterial disease. Vaatlijden van het been., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR2000031482: Study on drug interaction between Ilaprazole and Clopidogrel in healthy subjects |
|
|
| Not yet recruiting | 4 | 44 | | From D1 to D7, 75mg clopidogrel is taken orally once a day. From D18 to D24, 75mg clopidogrel and 10mg Ilaprazole are administered orally once a day. ;From D1 to D7, 75mg clopidogrel and 10mg Ilaprazole are administered orally once a day.From D18 to D24, 75mg clopidogrel is taken orally once a day. | The First Affiliated Hospital of Nanjing Medical University; Livzon Group Livzon Pharmaceutical Factory, enterprise self-raised | N/A | | | | |
ChiCTR1900025466: Efficacy and safety of tirofiban in the treatment of acute non-thrombolytic ischemic stroke: a randomized controlled trial. |
|
|
| Recruiting | 4 | 268 | | Saline+Tirofiban ;Aspirin +Clopidogrel or oral anticoagulant | The Affiliated Weihai Central Hospital of Qingdao University; The Affiliated Weihai Central Hospital of Qingdao University, National Natural Science Foundation and self raised fund | acute ischemic stroke | | | | |
2020-005156-38: Alternative biological mechanisms underlying thrombus formation in acute myocardial infarction. Meccanismi biologici alternativi alla base della formazione del trombo nell'infarto miocardico acuto. |
|
|
| Not yet recruiting | 4 | 36 | Europe | RIVAROXABAN, TICAGRELOR, Clopidogrel, [B01AF01], [B01AC24], [B01AC/04], Tablet, BRILIQUE | AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA, Università del Piemonte Orientale | acute ST-segment elevation myocardial infarction (STEMI) with large coronary thrombus burden (LCTB). infarto acuto del miocardio con elevazione del tratto ST (STEMI) con elevato carico trombotico, acute heart attack caused by the occlusion of a coronary artery by a large amount of thrombus. infarto acuto del cuore causato dall'occlusione di una arteria coronaria da parte di una grande quantità di trombo., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NXT-ASSESS, ChiCTR1800019496: A study for exploring the efficacy of Naoxintong Capsules in the treatment of coronary atherosclerotic Plaque on the basis of optimal medical therapy (Aspirin, Statins, Clopidogrel, etc.): Stage One |
|
|
| Not yet recruiting | 4 | 80 | | Naoxintong Capsule ;Placebo | Buchang Pharmaceuticals; FuWai Hospital Chinese Academy of Medical Sciences, Buchang Pharmaceuticals | Atherosclerotic Cardiovascular Disease | | | | |
BVS LATE, NCT02939872: Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events |
|
|
| Completed | 4 | 238 | RoW | aspirin and clopidogrel, Clopidogrel only | Seung-Jung Park, CardioVascular Research Foundation, Korea | Percutaneous Transluminal Coronary Angioplasty, Coronary Disease | 05/21 | 06/24 | | |
2020-006009-43: PROgnostic value of precision medicine in patients with Myocardial Infarction and non-obStructive coronary artEries: the PROMISE study. Valore prognostico della medicina di precisione nei pazienti con infarto miocardico a coronarie non ostruite: studio PROMISE |
|
|
| Not yet recruiting | 4 | 180 | Europe | TORVAST, Diltiazem, CARDIOASPIRIN, ACETIL SALICILATO DI LISINA, CLOPIDOGREL, Warfarin, TRINITRINA, SEQUACOR, RAMIPRIL, Miovisin, [TORVAST], [Diltiazem], [CARDIOASPIRIN], [ACETIL SALICILATO DI LISINA], [CLOPIDOGREL], [Warfarin], [TRINITRINA], [SEQUACOR], [RAMIPRIL], [Miovisin], Tablet, Solution for injection | FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, Ministero della Salute | Patients with Myocardial Infarction and non-obStructive coronary artEries Pazienti con infarto del miocardio a coronarie non ostruite, Patients with Myocardial Infarction and non-obStructive coronary artEries Pazienti con infarto del miocardio a coronarie non ostruite, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2021-000730-34: Comparison between single and dual therapy with drugs that inhibits platelet aggregation in patient undergoing the percutaneous left atrial appenDAge closure (ARMYDA-AMULET in which people will be allocated by chance to receive two different options of treatment and which will involves different clinical sites). Confronto tra singola e doppia terapia con farmaci in grado di ostacolare l'aggregazione piastrinica in pazienti sottoposti a chiusura percutanea di auricola sinistra (studio ARMYDA-AMULET in cui le due differenti opzioni di trattamento verranno assegnate in modo casuale e che si svolgerà in più centri clinici). |
|
|
| Not yet recruiting | 4 | 574 | Europe | clopidogrel 75, Aspirina 325, clopidogrel 300, Aspirina 100, [NA], Film-coated tablet, Tablet, Gastro-resistant tablet | FONDAZIONE TOSCANA GABRIELE MONASTERIO, Abbott Medical Italia Spa | Patients with atrial fibrillation undergoing percutaneous left atrial appendage closure with the Amulet device Pazienti con fibrillazione atriale sottoposti a chiusura percutanea dell'auricola sinistra con il dispositivo Amulet, Patient with irregular heartbeat undergoing percutaneous left atrial appendage closure Pazienti con alterazione del ritmo del cuore sottoposti a chiusura percutanea dell'auricola sinistra, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR1900025059: Effects of aspirin combined with ticagrelor or clopidogrel on stent thrombosis in coronary bifurcation lesions |
|
|
| Not yet recruiting | 4 | 600 | | aspirin combined with ticagrelor ;aspirin combined with clopidogrel | The Second Affiliated Hospital of Army Medical University; The Second Affiliated Hospital of Army Medical University, None | coronary bifurcation lesions | | | | |
| Not yet recruiting | 4 | 120 | | Aspirin 0.1 g / tablet, once a day, 1 tablet each time, clopidogrel 75 mg / tablet, once a day, 1 tablet each time; ;Aspirin, 0.1 g / tablet, once a day, 2 tablets each time | Zhongshan Hospital Affiliated to Fudan University; Zhongshan Hospital Affiliated to Fudan University, Clinical research project | 房间隔缺损 | | | | |
| Recruiting | 4 | 7700 | RoW | Clopidogrel, Clopidogrel+aspirin | Shenyang Northern Hospital | Prolonged DAPT in ACS Patients With Hisk of Both Ischemic and Hemorrhage | 09/21 | 09/21 | | |
ChiCTR1800020026: The efficacy and safety of aspirin in ischemic stroke with G6PD deficiency: a prospective, multi-center, and randomized controlled trial |
|
|
| Not yet recruiting | 4 | 400 | | aspirin (100 mg/d) ;clopidogrel (75 mg/d) | The First Affiliated Hospital, Sun Yat-sen University; Department of Neurology and Stroke Center, research funds | G6PD deficiency | | | | |
ESAT, ChiCTR1900022143: Early intravenous Anticoagulation treatment in acute ischemic Stroke patients with severity intracranial arterial sTenosis or Atrial fibrillation |
|
|
| Not yet recruiting | 4 | 400 | | 1. Aspirin 300mg, QD+clopidogrel 75mg, QD in the first 24 hours. 2. 2. Aspirin 100mg, QD+clopidogrel 75mg, QD from 2-90 days. ;1.intravenous argatroban 2.5mg/h within the first 48 hours and aspirin 100mg, QD; 2. intravenous argatroban 2.5mg/h*4 hours, BID and aspirin 100mg, QD+clopidogrel 75mg, QD from 3-6 days; 3.3. Aspirin 100mg, QD+clopidogrel 75mg, QD from 7-90 days. ;1.Aspirin 300mg, QD in the first 24 hours. 2.Aspirin 100mg, QD from 2-6 days. 3.Transition to oral anticoagulation therapy (new oral anticoagulant agent or warfarin with INR 2-3) from 7-9 days. 4.Oral anticoagulation therapy from 10-90 days. ;1.intravenous argatroban 2.5mg/h within the first 48 hours and aspirin 100mg, QD. 2. intravenous argatroban 2.5mg/h*4 hours, BID and aspirin 100mg, QD from 3-6 days. 3.Transition to oral anticoagulation therapy (new oral anticoagulant agent or warfarin with INR 2-3) from 7-9 days. 4. Oral anticoagulation therapy&# | Department of Neurology, The Second Affiliated Hospital of Soochow University; The Second Affiliated Hospital of Soochow University, 1.The project of suzhou key clinical diseases diagnosis and treatment technology 2018. 2. Young Elite Scientists Sponsorship Program by CAST 2018 | Acute ischemic stroke | | | | |
ChiCTR2100042709: Efficacy and safety of low-dose ticagrelor in patients with moderate and high risk of grace ischemia after PCI |
|
|
| Recruiting | 4 | 480 | | 90mg ticagrelor ;60mg ticagrelor ;75mg clopidogrel | Hebei Engineering University; Handan First Hospital, Postgraduate Funds | Acute, chronic coronary syndrome | | | | |
2019-004860-23: REACTIC-TAVI TRIAL: Platelet REACtivity according to TICagrelor dose after Trancathter Aortic Valve Implantation. A pilot study. Ensayo REACTIC-TAVI: REACtividad de plaquetas según la dosis de TICagrelor después de la implantación de la válvula aórtica Trancathter. Un estudio piloto. |
|
|
| Not yet recruiting | 4 | 40 | Europe | Tablet, Ticagrelor, Clopidogrel | Andres Iñiguez Romo, Hsopital Alvaro Cunquiero. Servicio de Cardiología | Patients with severe aortic stenosis submitted for Transcatheter Aortic Valve Implantation Pacientes con estenosis aórtica grave sometidos a implante de válvula aórtica transcatéter, Patients with severely narrow aortic valve who undergo replacement through catheters. Pacientes con la válvula aórtica severamente estrecha que se sometan a un recambio a través de catéteres., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR2100043135: Analysis of efficacy and safety of ticagrelor after interventional therapy in patients with acute coronary syndrome complicated with severe renal insufficiency |
|
|
| Recruiting | 4 | 100 | | ticagrelor +aspirin ;clopidogrel +aspirin | Yuebei People's Hospital; None, Bethune Medical Science Foundation | Acute myocardial infarction | | | | |
NCT04057300: Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes |
|
|
| Completed | 4 | 1038 | Canada | Ticagrelor 90mg, Brilinta, Clopidogrel 75mg, Plavix, acetylsalicylic acid (ASA) 81mg, Aspirin | McGill University Health Centre/Research Institute of the McGill University Health Centre, Canadian Institutes of Health Research (CIHR) | Acute Coronary Syndrome | 04/22 | 04/23 | | |
NCT03947229: A Randomized Comparison of CLOpidogrel Monotherapy Versus Extended Dual-antiplatelet Therapy Beyond 12 Months After Implantation of Drug-eluting StEnts in High-risk Lesions or Patients; A-CLOSE Trial |
|
|
| Active, not recruiting | 4 | 3200 | RoW | Clopidogrel mono-therapy, Dual-antiplatelet therapy | Yonsei University | Coronary Artery Disease, DES | | | | |
2020-004748-27: Patients who are diagnosed with atrial fibrillation and experienced an acute myocardial infarction treated with percutaneos coronary intervention will receive an intesified treatment combination of platelet inihibition and direct oral anticoagulation. |
|
|
| Not yet recruiting | 4 | 2334 | Europe | Prasugrel, Brilique, Clopidogrel, Acetylsalicylic Acid, Film-coated tablet, Tablet, Brilique | LMU University Hospital Munich, Daiichi-Sankyo Deutschland GmbH | Patients with atrial fibrillation and ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) (biomarker -positive acute coronary syndrome) undergoing PCI, Patients with atrial fibrillation and myocardial infarction in whom a percutaneous coronary intervention (treatment of the obstruction of the respective blood vessel) is performed., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR1900022390: The Comparison of Ticagrelor and Clopidogrel on Graft Patency after Coronary Artery Bypass Graft Surgery |
|
|
| Recruiting | 4 | 300 | | ticagrelor ;clopidogrel | Dalian Municipal Central Hospital; Dalian Municipal Central Hospital, self-finance | Coronary Heart Disease | | | | |
NCT03774394: Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus |
|
|
| Completed | 4 | 61 | US | Clopidogrel, Plavix, Clopidogrel active metabolite | University of Florida, Scott R. MacKenzie Foundation | Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD) | 05/22 | 05/22 | | |
2021-006611-29: A randomized trial studying the effect of antiplatelet therapy (clopidogrel, clopidogrel/ascal) on the prevention of atherothrombotic events after peripheral angioplasty Een gerandomiseerde studie naar het effect van bloedplaatjesremmers (clopidogrel, clopidogrel/aspirine) op het voorkomen van atherotrombotische events na perifere dotterbehandelingen. |
|
|
| Ongoing | 4 | 1696 | Europe | Tablet, Clopidogrel (Clopidogrel, Grepid, Iscover, plavix), acetylsalicylzuur (acetylsalicylzuur cardio) | University Medical Centre Utrecht Department of Vascular Surgery, ZonMW | (Chronic) Peripheral (occlusive) arterial disease (PAD) (Chronisch) Perifeer arterieel vaatlijden (PAV), Narrowed/blockage of arteries in the lower extremities verstopping in de slagaders van de benen, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR2100046487: Argatroban combined with clopidogrel and aspirin in preventing early neurological deterioration in patients with acute penetrating artery infarction：a prospective multicenter randomized controlled trial |
|
|
| Recruiting | 4 | 100 | | Argatroban combined with dual antiplatelet (argatroban+clopidogrel+aspirin) ;Dual antiplatelet (clopidogrel+aspirin） | Chengdu Second People's Hospital; Chengdu Second People's Hospital, Major Technology Application Demonstration Project of Chengdu Science and Technology Bureau (2019-YF09-00097-SN) | penetrating artery infarction (acute ischemic stroke) | | | | |
2021-005022-18: Preventing formation of blood clots due to atrial fibrillation, a cardiac arrhythmia that first occurred after coronary bypass surgery, with the help of anticoagulant medications. Vorbeugung der Bildung von Blutgerinnseln durch Vorhofflimmern, einer Herzrhythmusstörungen, die nach einer koronaren Bypass-Operation erstmalig aufgetreten ist, mit Hilfe von gerinnungshemmenden Medikatmenten. |
|
|
| Not yet recruiting | 4 | 3200 | Europe | Marcumar, Dabigatran, Xarelto, Apixaban, Edoxaban, Aspirin, Brilique, Clopidogrel, B01AC04, Tablet, Capsule, hard, Marcumar, Pradaxa, Xarelto, Eliquis, Lixiana, Aspirin, Brilique, Clopidogrel | Icahn School of Medicine at Mount Sinai, NIH/NHLBI | New-Onset Post-Operative Atrial Fibrillation afterCABG Neu auftretendes postoperatives Vorhofflimmernnach CABG, New-Onset Post-Operative Atrial Fibrillation aftercoronary artery bypass graft (bridging of constrictions in coronary vessels) Neu aufgetretenes Vorhofflimmern nach einerkoronaren Bypassoperation (Überbrückung von Engstellen in Herzkranzgefäßen), Diseases [C] - Cardiovascular Diseases [C14] | | | | |
